摘要
目的探讨进展期胃癌患者行新辅助化疗及手术后血清Her-2/neu ECD水平的变化及临床意义。方法采用双抗体夹心ELISA法检测海口市人民医院胃肠外科2011年2月～2012年6月42例进展期胃癌患者在新辅助化疗及手术前后血清Her-2/neu ECD水平,并统计根治手术率,进行统计学分析。结果 42例进展期胃癌患者行新辅助化疗后,血清Her-2/neu/neu ECD水平57.14%(24/42)下降,33.33%(14/42)未变化,9.52%(4/42)升高;化疗后血清Her-2/neu ECD水平下降组根治性切除率75.0%(18/24),化疗后血清Her-2/neu ECD水平升高、不变组根治性切除率44.44%(8/18),组间差异有显著性(P<0.05);而且根治性手术后患者与姑息术后患者血清Her-2/neu ECD水平下降率比较(分别为80.77%、31.25%),组间差异有显著性(P<0.05)。结论动态检测进展期胃癌患者新辅助化疗及手术前后血清Her-2/neu ECD水平变化对判断化疗、手术疗效及预后具有一定的临床意义。
【Objective】To evaluate the clinical implication of variations in serum Her-2/neu extracellular domain（ECD） levels before and after treatment of advanced gastric cancer patients.【Methods】Serum Her-2/neu ECD levels of 42 advanced gastric cancer patients before and after neoadjuvant chemotherapy or surgery were assayed by enzyme-linked immunosorbent assay（ELISA）.【Results】After neoadjuvant chemotherapy,24/42（57.14%） of serum Her-2/neu ECD levels in advanced gastric cancer patients were ruduced,14/42（33.33%） were no changed,and 4/42（9.52%） were risen;significant different rates of radical operation were found between the patients with ruduce levels of serum Her-2/neu ECD（75.0%,18/24） and the others（44.44%,8/18）,and P〈 0.05.80.77% of the serum Her-2/neu ECD levels in the patients with radical operation were reduced,and only 31.25% of the leves in the patients with palliative operation were reduced,showing significant difference between the two groups（P〈 0.05）.【Conclusion】Kinetic monitoring of the changes of serum Her-2/neu ECD levels in advanced gastric cancer patients may represent a valuable tool for evaluating clinical response to neoadjuvant chemotherapy and surgery.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2013年第15期70-72,共3页
China Journal of Modern Medicine
